Company Badge
USPTO Data Jan 1 1976 - Oct 20 2026
6 Patents
#324 in Cambridge, MA
#2,546 in Massachusetts
#45,007 in US
Elixir Pharmaceuticals, Inc.
Forward Citations = 16
15 inventors:
Cambridge, MA, United States of America
Elixir Pharmaceuticals, Inc.
% Expired Patents = 83.3
EPO Patents = 1
Forward Citations = 16
Loading Chart...
Loading Chart...
15 inventors (with patents filed for the assignee):
Jean-Francois Pons (4 out of 5 patents)
Manuel A Navia (3 out of 19 patents)
Jeffrey O Saunders (3 out of 68 patents)
4. Andrew Napper (3 out of 3 patents)
5. Peter DiStefano (3 out of 3 patents)
6. Rory A Curtis (3 out of 3 patents)
7. L Julie Huber (3 out of 3 patents)
8. Jonathan M Solomon (3 out of 4 patents)
9. Russell Thomas (2 out of 17 patents)
10. Jay R Luly (2 out of 61 patents)
11. Thomas Stephen Coulter (1 out of 13 patents)
12. Jeffrey Hixon (1 out of 1 patent)
13. Paul Mortenson (1 out of 1 patent)
14. Thomas E McDonagh (1 out of 5 patents)
15. Russell J Thomas (1 out of 1 patent)
6 patents:
Company Overview
Elixir Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for aging-associated diseases. Their research and development efforts are centered around utilizing small molecule drugs to target key pathways involved in aging and age-related illnesses. With a commitment to improving the health and quality of life for aging populations, Elixir Pharmaceuticals aims to bring groundbreaking treatments to market that address unmet medical needs in the aging space.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Elixir Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/elixir-pharmaceuticals
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
1 patent (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]